1 ene 2014 año - Pembrolizumab
Descripción:
Pembrolizumab is approved for advanced melanoma treatment by the FDA. This monoclonal antibody blocks a protein called PD1's activity on immune cells, which increases the strength of the immune response to cancer.
Añadido al timeline:
fecha:
1 ene 2014 año
Ahora mismo
~ 10 years ago